Rose bengal sodium is under clinical development by Provectus Biopharmaceuticals and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rose bengal sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rose bengal sodium overview

PV-10 is under development for the treatment of neuroendocrine tumors, hepatocellular carcinoma, metastatic colorectal cancer, uveal melanoma, metastatic melanoma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer and pediatric solid tumor including  neuroblastoma, relapsed or refractory acute myelomonocytic leukemia (AML) and acute lymphocytic leukemia, testicular cancer, liver cancer,  psoriasis, atopic dermatitis, pediatric solid tumor including  Ewing sarcoma, rhabdosarcoma, osteosarcoma. It acts by targeting serine/threonine-protein kinase WNK1. The drug candidate is administered as an intralesional injection, oral and topical route. PV-10 is a formulation of rose bengal disodium, which is an iodinated fluorescein derivative.

It was also under development for the treatment of basal cell carcinoma (basal cell epithelioma), squamous cell carcinoma, head and neck cancer, bladder cancer, breast cancer, prostate cancer and non-small cell lung cancer. 

Provectus Biopharmaceuticals overview

Provectus Biopharmaceuticals (Provectus) is a developer of pharmaceuticals for oncology and dermatology indications compmay. The company offers pipeline products such as PV-10 for locally advanced cutaneous melanoma, PV-10 for metastatic liver cancer and PV-10 for neuroendocrine tumors [NET], pediatric solid tumors and other tumors. It also involve in developing a new class of drugs based on halogenated xanthenes such as Rose Bengal. Provectus also offers PH-10 for psoriasis and atopic dermatitis. The company conducts research on ongoing clinical trials for indications including breast cancers, melanoma, head and neck cancers, basal cell carcinoma and squamous cell carcinoma. Provectus is headquartered in Knoxville, Tennessee, the US.

For a complete picture of Rose bengal sodium’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.